Netherlands· NL-79388ffd6e45
Priorix-Tetra, poeder en oplosmiddel in voorgevulde spuit voor oplossing voor injectie
A masern, kombinationen mit mumps, röteln und varicella, lebend abgeschwächt product, registered in Netherlands by GlaxoSmithKline B.V.. The same ATC class is registered in 10 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Masern, kombinationen mit mumps, röteln und varicella, lebend abgeschwächt is registered in 10 of 19 countries.
Countries holding a registration under ATC J07BD54 (masern, kombinationen mit mumps, röteln und varicella, lebend abgeschwächt), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 6 of them publish a price we can compare per daily dose
Masern, kombinationen mit mumps, röteln und varicella, lebend abgeschwächt · ATC J07BD54
10 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- Switzerlandprice
The record
At a glance
CBG-MEB (Netherlands)- Manufacturer
- GlaxoSmithKline B.V.
- Country
- Netherlands (NL)
- ATC code
- J07BD54
- ATC class
- Masern, Kombinationen mit Mumps, Röteln und Varicella, lebend abgeschwächt
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_id35077
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same class
Other records under J07BD54
Masern, kombinationen mit mumps, röteln und varicella, lebend abgeschwächt, as other registers publish it.
- FinlandPriorix TetraGlaxoSmithKline Biologicals SA
- FinlandPriorix TetraGlaxoSmithKline Biologicals SA
- IcelandPriorix-TetraGlaxoSmithKline Pharma A/S
- BelgiumPriorix-TetraGlaxoSmithKline Biologicals
- PolandPriorix-TetraGlaxoSmithKline Biologicals S.A.
- PolandPriorix-TetraGlaxoSmithKline Biologicals S.A.
- DenmarkPriorix-TetraGlaxoSmithKline Pharma A/S
- BelgiumPriorix-TetraGlaxoSmithKline Biologicals
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/efb48bee-881f-48b9-bfe5-b242d1142733 GET /v1/drugs/efb48bee-881f-48b9-bfe5-b242d1142733?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Poeder en oplosmiddel voor oplossing voor injectie",
"route": "Subcutaan gebruik",
"soort": "RVG",
"source": "cbg_meb",
"smpc_url": "https://www.geneesmiddeleninformatiebank.nl/smpc/h35077_smpc.pdf",
"strength": null,
"atc_label": "Measles, Combinations With Mumps, Rubella And Varicella, Live Attenuated",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/rvg35077",
"excipients": [
"AMINOZUREN (AANTAL 15)",
"LACTOSE 0-WATER",
"MANNITOL (D-) (E 421)",
"MEDIUM 199",
"SORBITOL (E 420)",
"WATER VOOR INJECTIE"
],
"substances": [
"LEVEND VERZWAKT BOFVIRUSVACCIN, stam RIT 4385 AFGELEID VAN stam Jeryl Lynn, gekweekt in CEF cellen",
"LEVEND VERZWAKT MAZELENVIRUSVACCIN, stam Schwarz gekweekt in CEF cellen",
"LEVEND VERZWAKT RUBELLAVIRUSVACCIN, stam Wistar RA 27-3 geproduceerd in Humaan diploïde cellijn MRC5",
"LEVEND VERZWAKT VARICELLAVIRUSVACCIN, stam OKA geproduceerd in Humaan diploïde cellijn MRC5"
],
"leaflet_url": "https://www.geneesmiddeleninformatiebank.nl/bijsluiters/h35077.pdf",
"authorised_at": "2007/08/13",
"procedure_number": "DE/H/0468/001",
"dispensing_status": "Uitsluitend recept",
"registration_number": "35077",
"additional_monitoring": "N"
}See everything about masern, kombinationen mit mumps, röteln und varicella, lebend abgeschwächt.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.